骨氏葆方联合膝关节内粘疗法对膝骨关节炎患者骨代谢的影响及其有效性、安全性临床研究  

The efficacy and safety of the Gushibao prescription plus knee intramuscular therapy on bone metabolism in patients with knee osteoarthritis

作　　者：任伟亮[1] 

机构地区：[1]河北省中医院,河北石家庄050011

出　　处：《中医临床研究》2017年第7期11-13,共3页Clinical Journal Of Chinese Medicine

基　　金：河北省中医药管理局科研课题;编号为2016166

摘　　要：目的:研究骨氏葆方治疗膝骨关节炎的有效性、安全性及对骨代谢指标的影响。方法:选取我院收治的100例膝骨关节炎患者为研究对象,随机分成两组,各50例。对照组采用盐酸氨基葡萄糖胶囊治疗,观察组口服骨氏葆方治疗。比较两组患者症状评分及相关指标变化。结果:治疗后两组患者降钙素及骨型碱性磷酸酶指标相比,无明显差异(P>0.05);观察组血沉指标明显低于对照组,差异显著(P<0.05);治疗后两组症状评分均显著降低,且观察组降低趋势大于对照组,差异显著(P<0.05);两组患者治疗中均未出现严重不良反应,且所有患者进行血常规、肝肾功能的动态监测,均未发现明显异常变化,两组治疗前后肝肾功能指标相比均无明显差异(P>0.05)。结论:骨氏葆方治疗膝骨关节炎效果显著,安全性高,具有较高的临床应用价值。Objective:To study the efficacy and safety of the Gushibao prescription on knee osteoarthritis and bone metabolism.Methods:100patients were randomly divided into two groups,50cases in each.The control group was treated with aminoglucose hydrochloride;the observation group was treated with the Gushibao prescription.Results:There was no significant difference in calcitonin and bone alkaline phosphatase between groups(P>0.05).The ESR in the observation group was significantly lower,with a significant difference(P<0.05).The scores in groups were significantly lower;and that in the observation group was more significant(P<0.05).There was no serious adverse reaction.The blood,liver and kidney function of all patients showed no significant differences(P>0.05).Conclusion:The Gushibao prescription on knee osteoarthritis is effective and safe,and shows high clinical value.

关 键 词：骨氏葆方 膝骨关节炎 安全性 

分 类 号：R322.72[医药卫生—人体解剖和组织胚胎学]